Healthcare Startup Preventify Raises Rs 2 Cr in Pre-Seed Round Led by PedalStart

Why It Matters

The capital infusion accelerates scalable, cost‑effective healthcare delivery in underserved Indian regions, signaling strong investor confidence in preventive‑care models. It also positions Preventify to capture a growing market for chronic disease management beyond metropolitan hubs.

Key Takeaways

• Rs 2 crore pre‑seed secured
• Cluster model targets tier‑II/III markets
• 10‑clinic rollout planned in Kerala
• Subscription managed‑care programs under development
• PedalStart provides accelerator support

Pulse Analysis

India’s healthtech landscape is witnessing a shift from urban‑centric telemedicine to localized, clinic‑based networks that address chronic disease burdens in smaller cities. Preventify’s recent pre‑seed raise reflects this trend, as investors increasingly back models that blend physical infrastructure with digital monitoring. By targeting tier‑II and tier‑III districts, the startup taps into a population segment that traditionally faces limited access to consistent preventive care, creating a sizable addressable market for its protocol‑driven services.

The company’s cluster expansion strategy—standardising care delivery across a network of ten clinics—offers economies of scale while maintaining localized patient relationships. Integrating diagnostics, pharmacy, and remote monitoring into a unified tech stack enables data‑driven treatment pathways, reducing readmission rates for conditions like diabetes and hypertension. Moreover, the rollout of subscription‑based managed‑care programs promises predictable revenue streams and higher patient retention, aligning financial incentives with health outcomes.

For investors, Preventify’s funding round underscores confidence in scalable, hybrid healthcare models that can bridge the gap between primary care and specialist services in non‑metro areas. PedalStart’s accelerator role adds operational expertise, potentially accelerating market penetration and attracting follow‑on capital. As chronic disease prevalence rises across India, startups that can deliver cost‑effective, continuous care are poised to become pivotal players in the nation’s broader health ecosystem.

Healthcare startup Preventify raises Rs 2 Cr in pre-seed round led by PedalStart

By Shashank Pathak · 09 Feb 2026 13:19 IST · Image: Preventify

Healthcare Preventify has raised Rs 2 crore in a pre‑seed funding round led by PedalStart. The round also saw participation from angel investors including Viren Shetty of Narayana Health, Jatin Kakrani of Dezy, founders of Supertails, founders of Agrizy, and senior executives from the healthcare sector.

The proceeds will be used to build its first cluster of 10 clinics, expand chronic and lifestyle disease‑management programs, and strengthen its technology stack along with diagnostics and pharmacy integration. The firm follows a cluster‑based expansion strategy to standardise care delivery and manage costs.

Founded by Nirmal NR and Dr. Rakesh, Preventify operates a clinic‑led healthcare model focused on preventive and chronic care delivery in tier‑II and tier‑III markets. The startup currently runs three clinics in Kerala and has served over 40,000 patients, according to the company.

Preventify focuses on managing chronic conditions such as diabetes, hypertension, and respiratory diseases through protocol‑driven care models. The startup combines in‑clinic consultations with digital monitoring and structured follow‑ups.

Over the next 12–18 months, Preventify plans to scale its clinic footprint across Kerala and invest in clinicians, nurses, care coordinators, and central medical teams. It is also developing subscription‑based managed‑care programs to improve continuity of care.

PedalStart will work closely with Preventify as an accelerator partner, supporting the company on growth strategy, operational processes, and expansion planning.

---

Disclaimer:

Bareback Media has recently raised funding from a group of investors. Some of the investors may directly or indirectly be involved in a competing business or might be associated with other companies we might write about. This shall, however, not influence our reporting or coverage in any manner whatsoever. You may find a list of our investors here.